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ABSTRACT
Objectives: Evidence to guide fluid resuscitation
evidence in sepsis continues to evolve. We
conducted a multicountry survey of emergency and
critical care physicians to describe current stated
practice and practice variation related to the
quantity, rapidity and type of resuscitation fluid
administered in early septic shock to inform the
design of future septic shock fluid resuscitation
trials.
Methods: Using a web-based survey tool, we
invited critical care and emergency physicians in
Canada, the UK, Scandinavia and Saudi Arabia to
complete a self-administered electronic survey.
Results: A total of 1097 physicians’ responses
were included. 1 L was the most frequent quantity
of resuscitation fluid physicians indicated they
would administer at a time (46.9%, n=499). Most
(63.0%, n=671) stated that they would administer
the fluid challenges as quickly as possible. Overall,
normal saline and Ringer’s solutions were the
preferred crystalloid fluids used ‘often’ or ‘always’ in
53.1% (n=556) and 60.5% (n=632) of instances,
respectively. However, emergency physicians
indicated that they would use normal saline ‘often’
or ‘always’ in 83.9% (n=376) of instances, while
critical care physicians said that they would use
saline ‘often’ or ‘always’ in 27.9% (n=150) of
instances. Only 1.0% (n=10) of respondents
indicated that they would use hydroxyethyl starch
‘often’ or ‘always’; use of 5% (5.6% (n=59)) or 20–
25% albumin (1.3% (n=14)) was also infrequent.
The majority (88.4%, n=896) of respondents
indicated that a large randomised controlled trial
comparing 5% albumin to a crystalloid fluid in early
septic shock was important to conduct.
Conclusions: Critical care and emergency
physicians stated that they rapidly infuse volumes of
500–1000 mL of resuscitation fluid in early septic
shock. Colloid use, specifically the use of albumin,
was infrequently reported. Our survey identifies the
need to conduct a trial on the efficacy of albumin
and crystalloids on 90-day mortality in patients with
early septic shock.
BACKGROUND
Fluid resuscitation is a vital first-line interven-
tion for all patients with septic shock.
Management guidelines recommend rapid
administration of resuscitation fluid to achieve
a minimum of 30 mL/kg in the early hours
of resuscitation, with the goal of regaining
haemodynamic stability, optimising organ per-
fusion and ultimately improving outcomes
and preventing death.1 While fluid resuscita-
tion is a life-saving intervention, until recently,
high-quality evidence to guide fluid choice
and resuscitation practices has been lacking.
In recent years, there has been an accumu-
lation of evidence regarding fluid resuscitation
Strengths and limitations of this study
▪ This survey included a large sample of emer-
gency and critical care physicians’ stated early
septic shock resuscitation practices from
Canada, the UK, Scandinavia and Saudi Arabia.
▪ The survey was designed to be short, simple
and specific to the early resuscitative phase of
septic shock so that it would take at most 5 min
to complete.
▪ Since the survey focused on the early resuscita-
tive phase of septic shock, the responses to
questions may not be generalisable to later
phases of septic shock or specific subpopula-
tions of patients with septic shock.
▪ Owing to the variable methods used for survey
distribution, we could not summarise an accur-
ate response proportion.
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that has served both to change practice and prompt
further resuscitation research questions. For example, a
multicentre paediatric trial from East Africa of predom-
inantly malaria-infected children with severe fever and
hypoperfusion questioned how aggressively we should
administer resuscitation fluids in this setting.2 This trial
found that fluid boluses, as compared with the adminis-
tration of intravenous maintenance fluids, increased the
risk of death at 48 hours. The results of these research
findings have encouraged other investigators to further
study aggressive versus conservative fluid resuscitation
strategies for children and adults with septic shock in the
emergency department (ED) and intensive care unit and
clinical trials are ongoing or recently completed (Clinical
Trials.gov NCT02079402 and NCT01973907, respect-
ively). Evidence has also emerged to help guide practice
with regard to the use of colloid fluids in sepsis. In 2004,
our group conducted a survey of early septic shock resus-
citation practices of Canadian critical care physicians
and found that hydroxyethyl starch (HES) fluid was used
commonly, reportedly 51% of the time.3 An international
cross-sectional study of fluid resuscitation episodes in the
intensive care unit conducted in 2007 also documented
frequent colloid fluid use (48% of episodes) and 44% of
colloids administered were HES fluids.4 Since the publi-
cation of these studies, data from randomised trials and
systematic reviews have demonstrated clear harms caused
by HES in critically ill patients, particularly those with
sepsis.5–9 Although a recent systematic review of albumin
in sepsis found no overall mortality benefit,10 two sub-
group analyses from recent randomised trials comparing
albumin to crystalloid fluid in the critically ill and severe
sepsis and septic shock found reductions in mortality at
28 and 90 days, respectively.11 12
In the context of evolving literature to guide practice,
we conducted an early septic shock fluid resuscitation
survey to inform the design and provide justification for
future early septic shock fluid resuscitation trials com-
paring 5% albumin versus crystalloid fluid on 90-day
mortality. Our survey had two objectives: (1) to describe
practice variation among emergency and critical care
physicians regarding the quantity, rapidity and type of
fluid administered during early septic shock resuscita-
tion and (2) to elicit views of a future early septic shock
fluid resuscitation trial comparing 5% albumin versus
crystalloid fluid on 90-day mortality by eliciting from
respondents the minimal clinically important difference
(MCID) between fluid intervention and control arms
that would inform their practice, as well understanding
the perceived importance of and respondents’ willing-
ness to enrol into such a future trial.
METHODS
Identification of study participants and survey distribution
Our target population consisted of critical care and
emergency physicians in Canada, the UK, Scandinavia
and Saudi Arabia who provide care for adult patients
(≥18 years of age) with septic shock. These countries
were selected because research and opinion leaders in
these countries had expressed interest in collaborating
on an international trial on early fluid resuscitation.
Participants were contacted by their respective critical
care or emergency medicine professional societies in the
UK and Canada, and through direct contact with lead
site investigators in Canada, Scandinavia (including the
countries Norway, Sweden, Finland and Denmark) and
Saudi Arabia using a standardised email containing a
weblink to the survey. Respondents activated the weblink
and completed the survey instrument online. The survey
was distributed in January and February 2014. To maxi-
mise responses, non-respondents received up to two
email reminders.
Survey development
We generated items for the survey instrument through
literature review and consultation with international
investigators representing emergency and critical care
medicine. Items were reduced and formatted to reduce
respondent burden and maximise the response rate.
The survey was pilot tested by our investigative team and
critical care research fellows at the University of Ottawa
in Ottawa, Canada, for clinical sensibility and with a
target time to completion of 5 min. The survey was struc-
tured using a web-based survey platform (FluidSurveys).
Research ethics board approval was sought as required
by lead investigators for each country that participated
in the survey.
Survey content
The survey presented a typical patient with early septic
shock in the ED (see survey, online supplementary
appendix 1). This patient was introduced as a
55-year-old 70 kg female who had just arrived in the ED
with suspected septic shock. She was confused, with a
blood pressure of 70/30, heart rate 135 bpm, respiratory
rate of 25 breaths per minute, temperature 39.5°C and
oxygen saturation of 96% on 3 L by nasal prongs. She
had already received a total of 1 L of normal saline over
15 min in the ED.
Respondents were then asked a series of questions:
the first was to document the quantity and rapidity of
fluid administration, and the second question examined
the type of resuscitation fluids that they would use in a
‘typical’ and an ‘ideal’ situation to resuscitate the patient
described above. An ‘ideal’ situation was proposed for
respondents to ascertain the fluid type given that a phys-
ician may wish to give a fluid, but that fluid may not be
readily available to them in practice (eg, fluid not
stocked or immediately available in the department).
For each of these questions, respondents answered on
the basis of a five-point Likert scale (ie, never, rarely,
sometimes, often, always). For the type of resuscitation
fluid question (survey questions 2a and 2b), Ringer’s
solutions (ie, Ringer’s lactate, Ringer’s acetate and
Hartmann’s solutions) were bundled together as one
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response option, reflecting their biochemical similarity13
and reducing respondent question burden.
To inform the design of an early septic shock fluid
resuscitation trial comparing 5% albumin to a crystalloid
fluid on the primary outcome of 90-day mortality, we
asked respondents to provide their views on an estimate
of the MCID between the fluid intervention and control
arms that would be required to inform their practice
(response options: 1%, 2.5%, 5%, 7.5% and 10%). Two
further questions were posed to determine the perceived
importance of (response options: not at all important,
not very important, somewhat important, important,
very important) and their willingness to enrol patients
into such a trial (response options: yes, no).
We also documented respondents’ primary specialty
and their practice experience in emergency medicine
and/or critical care.
Survey data collection and analysis
All data were collected electronically through FluidSurveys
(Ottawa, Ontario, Canada) and were housed and
managed on FluidSurveys’ secure servers. Prior to ana-
lysis, raw data were exported to Microsoft Excel (V.2010,
Redmond, Washington, USA) for cleaning and then
exported to SAS (V.9.2, by SAS Institute, Cary, North
Carolina, USA) for analysis.
All data are presented with numbers and proportions
for dichotomous and categorical variables, and with
means and SDs or medians and IQRs for continuous
variables, as appropriate. Missing responses were not
imputed. The five-point Likert scale responses were com-
bined into ‘often or always’, ‘sometimes’ and ‘rarely or
never’ for purposes of data presentation. The data for
all respondents were also described according to
whether respondents were critical care or emergency
medicine physicians. No sample size calculation was con-
ducted a priori since main survey intent was to be
descriptive. Post hoc, we calculated absolute differences
(ADs) in proportions and 95% CIs between typical and
ideal fluid use for all respondents and by primary spe-
cialty (critical care physicians and emergency physi-
cians), respectively. Differences in proportions with 95%
CIs for emergency and critical care physicians for typical
and ideal fluid were also calculated.
RESULTS
Study sample
A total of 1139 physicians responded to the survey; 16
respondents were not emergency or critical care physi-
cians, a further 15 did not provide care for adult patients
with septic shock, and 11 physicians did not respond to
one (n=10) or both (n=1) of these questions. Thus, a
total of 1097 physicians’ responses were included in the
final results. Of these, 64% (n=702) were from the UK,
26% (n=290) were from Canada and the remaining 10%
(n=105) were from Saudi Arabia (6.6%, n=72) and
Scandinavia (3.0%, n=33).
Demographics and training
A total of 90% (n=985) of physicians responded to the
primary specialty question. Of these responses, 45.5%
(n=448) of physicians indicated that their primary spe-
cialty was emergency medicine. The average number of
years spent in clinical practice was 10 (SD=8).
Quantity and rapidity of administration of resuscitation fluids
When we asked physicians about the quantity of resuscita-
tion fluid that they would typically administer at a time to
our hypothetical patient with early septic shock in the ED,
the most common answer was 1 L of fluid (46.9%, n=499),
followed by 500 mL (32.0%, n=340; see table 1). When
examined by primary specialty, 1 L (62.3%, n=279) and
500 mL (41.5%, n=223) were the most frequent responses
for emergency and critical care physicians, respectively.
Most physicians (63%, n=671) stated that they would
administer the fluid challenges as quickly as possible; this
response remained the most frequent when the data were
examined by emergency and critical care physicians
(73.2%, n=328 and 56.4%, n=303, respectively).
Type of resuscitation fluid typically and ideally administered
Normal saline and Ringer’s solutions were used typically
‘often’ or ‘always’ for early septic shock resuscitation
Table 1 Quantity and rapidity of fluid resuscitation by all
respondents, critical care and emergency physicians
Quantity n (%) Rapidity n (%)
(n=1064) (n=1065)
All respondents
100 mL 2 (0.2) 5 min 66 (6.2)
250 mL 123 (11.6) 10 min 98 (9.2)
500 mL 340 (32.0) 15 min 131 (12.3)
750 mL 9 (0.8) 30 min 81 (7.6)
1000 mL 499 (46.9) 1 hour 18 (1.7)
Other 91 (8.6) As quickly as
possible
671 (63.0)
(n=537) (n=537)
Critical care physicians
100 mL 2 (0.4) 5 min 45 (8.4)
250 mL 86 (16.0) 10 min 64 (11.9)
500 mL 223 (41.5) 15 min 75 (14.0)
750 mL 6 (1.1) 30 min 42 (7.8)
1000 mL 194 (36.1) 1 hour 8 (1.5)
Other 26 (4.8) As quickly as
possible
303 (56.4)
(n=448) (n=448)
Emergency physicians
100 mL 0 (0) 5 min 12 (2.7)
250 mL 21 (4.7) 10 min 25 (5.6)
500 mL 90 (20.1) 15 min 43 (9.6)
750 mL 3 (0.7) 30 min 35 (7.8)
1000 mL 279 (62.3) 1 hour 5 (1.1)
Other 55 (12.3) As quickly as
possible
328 (73.2)
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53.1% (n=556) and 60.5% (n=632) of the time, respect-
ively (see figure 1 and table 2). In contrast, respondents
infrequently used Plasma-Lyte (10.1%, n=106), 5%
albumin (5.6%, n=59), 20–25% albumin (1.3%, n=14)
and gelatin (7.0%, n=73) ‘often’ or ‘always’ in early
resuscitative efforts. Only 1.0% (n=10) of respondents
indicated that they would use HES ‘often’ or ‘always’ in
the resuscitative phase of septic shock.
When asked about the use of these fluids in the ideal
setting where they would be immediately available, use
of Plasma-Lyte and 5% albumin ‘often’ or ‘always’
increased the most (Plasma-Lyte from 10.1% (n=106) to
25.3% (n=264; AD=−15.2%; 95% CI −17.5% to −12.9%)
and 5% albumin from 5.6% (n=59) to 12.4% (n=129;
AD=−6.7%; 95% CI −8.3% to −5.0%; see figure 2 and
online supplementary table S1)).
When the typical use of crystalloid fluids was exam-
ined by primary specialty, emergency physicians indi-
cated that they would use normal saline ‘often’ or
‘always’ 83.9% (n=376), in contrast to critical care physi-
cians, who said that they would use saline 27.9% (n=150;
AD=56.0%; 95% CI 50.9% to 61.1%; see figure 1 and
online supplementary table S1). In the ideal setting,
where these fluids would be immediately available, the
two fluid-type responses that increased the most for
emergency physicians were Ringer’s solutions from
35.3% (n=158) to 45.1% (n=202; AD=−9.8; 95% CI
−13.3 to −6.4) and Plasma-Lyte from 2.9% (n=13) to
11.4% (n=51; AD=−8.5; 95% CI −11.2 to −5.8; see
figure 2, online supplementary table S1). The two fluid-
type responses that increased the most in the ideal
setting for critical care physicians were Plasma-Lyte
(from 15.3% (n=82) to 36.5% (n=196), AD=−21.2; 95%
CI −24.9 to −17.6) and 5% albumin (from 10.6%
(n=57) to 20.5% (n=110), AD=−9.9; 95% CI −12.6 to
−7.1).
A summary of typical and ideal fluid use by country is
provided in online supplementary table S2 and figures
S1 and S2, respectively.
Views on a future early septic shock fluid resuscitation trial
Most respondents indicated that the MCID for a future
trial comparing 5% albumin and a crystalloid fluid on
90-day mortality for early septic shock that would be
required to maintain or change their practice was 5%
(53.6%, 539/1005). Respondents also indicated that a
large randomised controlled trial comparing 5%
albumin to a crystalloid fluid with a primary outcome of
90-day mortality was important to conduct as 88.4%
(896/1014) of respondents indicated that the trial was
somewhat important (24.0%, 243/1014), important
(39.4%, 400/1014) or very important (25%, 253/1014).
Furthermore, 84.4% (851/1008) of respondents indi-
cated that they would be willing to enrol patients into
such a future clinical trial.
DISCUSSION
Results of our multicountry survey suggest that emer-
gency and critical care physicians who assess and
Figure 1 The Y-axis depicts the proportion of respondents that answered never/rarely, sometimes or often/always to each
typical resuscitation fluid type. The X-axis includes each typical resuscitation fluid type according to all respondents, emergency
physicians and critical care physicians. The response for Ringer’s solutions could reflect typical use of Ringer’s lactate, Ringer’s
acetate or Hartmann’s solutions, since these solutions were bundled into one response option in survey question 2a. ALL, all
respondents; CCP, critical care physicians; EP, emergency physicians.
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Table 2 Type of resuscitation fluid typically and ideally administered by all respondents, critical care and emergency physicians
Typically administered Ideally administered
Number Never/rarely Sometimes Often/always Number Never/rarely Sometimes Often/always
Type Respondents n (%) n (%) n (%) Respondents n (%) n (%) n (%)
All respondents
Normal saline (n=1047) 300 (28.7) 191 (18.2) 556 (53.1) (n=1045) 384 (36.7) 165 (15.8) 496 (47.5)
Ringer’s solutions (n=1045) 261 (25.0) 152 (14.5) 632 (60.5) (n=1044) 232 (22.2) 141 (13.5) 671 (64.3)
Plasma-Lyte (n=1045) 894 (85.6) 45 (4.3) 106 (10.1) (n=1043) 716 (68.7) 63 (6.0) 264 (25.3)
5% albumin (n=1045) 873 (83.5) 113 (10.8) 59 (5.6) (n=1044) 740 (70.9) 175 (16.8) 129 (12.4)
20% or 25% albumin (n=1044) 960 (92.0) 70 (6.7) 14 (1.3) (n=1043) 911 (87.3) 101 (9.7) 31 (3.0)
Hydroxyethyl starch (n=1044) 1023 (98.0) 11 (1.1) 10 (1.0) (n=1044) 1017 (97.4) 15 (1.4) 12 (1.1)
Gelatin (n=1045) 868 (83.1) 104 (10.0) 73 (7.0) (n=1044) 903 (86.5) 82 (7.9) 59 (5.7)
Critical care physicians
Normal saline (n=537) 249 (46.4) 138 (25.7) 150 (27.9) (n=537) 300 (55.9) 114 (21.2) 123 (22.9)
Ringer’s solutions (n=537) 35 (6.5) 65 (12.1) 437 (81.4) (n=537) 51 (9.5) 56 (10.4) 430 (80.1)
Plasma-Lyte (n=537) 426 (79.3) 29 (5.4) 82 (15.3) (n=537) 297 (55.3) 44 (8.2) 196 (36.5)
5% albumin (n=537) 383 (71.3) 97 (18.1) 57 (10.6) (n=537) 310 (57.7) 117 (21.8) 110 (20.5)
20% or 25% albumin (n=537) 466 (86.8) 58 (10.8) 13 (2.4) (n=537) 442 (82.3) 71 (13.2) 24 (4.5)
Hydroxyethyl starch (n=537) 522 (97.2) 7 (1.3) 8 (1.5) (n=537) 521 (97.0) 7 (1.3) 9 (1.7)
Gelatin (n=537) 394 (73.4) 77 (14.3) 66 (12.3) (n=537) 426 (79.3) 58 (10.8) 53 (9.9)
Emergency physicians
Normal saline (n=448) 28 (6.3) 44 (9.8) 376 (83.9) (n=448) 61 (13.6) 41 (9.2) 346 (77.2)
Ringer’s solutions (n=448) 211 (47.1) 79 (17.6) 158 (35.3) (n=448) 170 (37.9) 76 (17.0) 202 (45.1)
Plasma-Lyte (n=448) 422 (94.2) 13 (2.9) 13 (2.9) (n=448) 381 (85.0) 16 (3.6) 51 (11.4)
5% albumin (n=448) 434 (96.9) 13 (2.9) 1 (0.2) (n=448) 384 (85.7) 47 (10.5) 17 (3.8)
20% or 25% albumin (n=448) 441 (98.4) 7 (1.6) 0 (0) (n=448) 423 (94.4) 20 (4.5) 5 (1.1)
Hydroxyethyl starch (n=448) 444 (99.1) 3 (0.7) 1 (0.2) (n=448) 437 (97.5) 8 (1.8) 3 (0.7)
Gelatin (n=448) 425 (94.9) 21 (4.7) 2 (0.4) (n=448) 424 (94.6) 21 (4.7) 3 (0.7)
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manage adult patients in the early resuscitative phase of
septic shock prefer that fluid challenges (at least
500 mL) be administered as quickly as possible. When
examined by primary specialty, critical care physicians
indicated a preference to use Ringer’s solutions com-
pared with emergency physicians who indicated a prefer-
ence to use normal saline. Although the reported use of
Plasma-Lyte was infrequent, our survey data suggest that
both emergency and critical care physicians would use
more of this crystalloid fluid if it was readily available to
them. Use of HES fluid was uncommon and the
reported use of albumin (5% or 20–25%) was infre-
quent, although critical care physicians also indicated
that they would use albumin more frequently if it was
immediately available to them.
An abundance of observational evidence from large
propensity-matched cohort studies in the surgical14 15
and critically ill16 populations, and a prospective sequen-
tial period study17 in the critically ill suggest that high-
chloride fluids (eg, normal saline) may be associated
with excess mortality compared with lower chloride
fluids such as Ringer’s solutions or Plasma-Lyte. In add-
ition, normal saline resuscitation has been associated
with the subsequent use of renal replacement therapy,
increased postoperative infections and prolonged length
of stay in hospital.14–17 A recently published pilot trial
examined normal saline versus Plasma-Lyte for fluid
resuscitation in the intensive care unit.18 Investigators
did not detect an increased risk of acute kidney injury
or failure, or an increased risk of requirement for renal
replacement therapy with normal saline. However, the
study was underpowered for these clinical outcomes and
a larger trial with death as the primary end point is now
planned (NCT02721654). Both our survey and a similar
survey conducted in Scotland19 suggest that emergency
physicians prefer using normal saline, while critical care
physicians prefer Ringer’s solutions in septic shock. The
variability in stated practice between emergency and crit-
ical care physicians that was evident in our survey may
reflect an absence of high-quality evidence to support
the preference of either of these fluids, although a
recent network meta-analysis of randomised controlled
fluid trials in sepsis found that balanced crystalloids such
as Ringer’s or Plasma-Lyte as compared with normal
saline were associated with a reduced odds of death.20
However, since the reported use of Ringer’s solutions
and Plasma-Lyte further increased when presented with
an ‘ideal’ but still theoretical scenario in our survey, lack
of availability of these fluids or unit-specific policies or
protocols21 may contribute to the reported practice vari-
ability we identified.
Very few emergency and critical care physicians indi-
cated that they would use HES boluses in the early resus-
citative phase of septic shock. This contrasts sharply to a
septic shock resuscitation survey from 2004 in which
Canadian critical care physicians reported that they
would use HES fluids for early septic shock resuscitation
51% of the time. In the European intensive care unit
fluid challenge observational study conducted in 2013,
HES use accounted for only 10.8% of all fluid
Figure 2 The Y-axis depicts the proportion of respondents that answered never/rarely, sometimes or often/always to each ideal
resuscitation fluid type. The X-axis includes each ideal resuscitation fluid type according to all respondents, emergency
physicians and critical care physicians. The response for Ringer’s solutions could reflect ideal use of Ringer’s lactate, Ringer’s
acetate or Hartmann’s solutions since these solutions were bundled into one response option in survey question 2b. ALL, all
respondents; CCP, critical care physicians; EP, emergency physicians.
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challenges in the study.21 This apparent change in prac-
tice is most likely related to high-quality evidence from
randomised controlled trials and systematic reviews in
the past decade that now confirm that starch fluids
increase the risk of death and the use of renal replace-
ment therapy in patients with severe sepsis and septic
shock.6 7 9
According to our survey results, the use of albumin in
the early septic shock setting also remains infrequent
despite the SAFE (A Comparison of Albumin to Saline
for Fluid Resuscitation in the Intensive Care Unit)
severe sepsis subgroup analysis that suggested that 4%
albumin compared with normal saline was associated
with a significant reduction in 28-day mortality. After the
conduct of this survey in 2014, the ALBIOS trial
(Albumin Replacement for Patients with Severe Sepsis
and Septic Shock) which compared 20% albumin with
crystalloids versus crystalloids alone for patients with
severe sepsis and septic shock was published. The
ALBIOS trial found a mortality benefit at 90 days for
20% albumin in a post hoc analysis of patients with
septic shock but not in those with severe sepsis.12 If prac-
tice was influenced by that trial, it is possible that the
albumin responses in our survey under-represent
current use in early septic shock.
This survey has several weaknesses. A denominator
could not be calculated to ascertain a response propor-
tion because of the variable methods we used to distrib-
ute the survey. Although we obtained responses from
∼1000 critical care and emergency medicine physicians
from Canada, the UK, Saudi Arabia and Scandinavia, we
cannot confirm that the responses generated are repre-
sentative of the countries or regions. Resuscitation ques-
tions were asked in relation to one hypothetical early
septic shock scenario and, as such, it is not possible to
comment on fluid resuscitation practices, according to
physician characteristics, for patients in the later phase
of septic shock or with specific physiological character-
istics (eg, hypoalbuminaemia), or chronic morbidities.
However, this survey was large (∼1000 responses), and it
includes the stated preferences of critical care and emer-
gency medicine physicians, which are divergent with
regard to the quantity and type of resuscitation fluid used
for early septic shock resuscitation. Although answers to
questions related to other aspects of septic shock manage-
ment were not obtained, they provide robust information
regarding the fluid resuscitation practices of a wide
variety of physicians managing patients in the early resus-
citative phase of septic shock. Furthermore, the survey
was designed to be brief and take <5 min to complete to
maximise responses to each question. That goal was
achieved, since at least 95% of respondents answered
each of the resuscitation questions.
In summary, in the resuscitative phase of septic shock,
emergency and critical care physician practices as stated
in this survey are to administer volumes of resuscitation
fluid most commonly in the range of 500–1000 mL at a
time. It is important to note that these volumes are
within the current surviving sepsis resuscitation guidelines
that recommend a minimum achievement of 30 mL/kg in
the early hours of resuscitation since our aim was to elicit
details of how much bolused resuscitation fluid would be
administered at a time during early septic shock.1
Although normal saline and Ringer’s solutions are the two
most common crystalloid fluids, stated preferences differ
between emergency and critical care physicians. Most phy-
sicians support a future trial of albumin compared with
crystalloid fluid in the early phase of septic shock.
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